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Abstract. The study analyzes the effectiveness of short-term and long-term treatment of West syndrome with 
the help of different antiepileptic drugs (AEDs) (combined therapy with the inclusion of Tetracosactide in comparison 
with nonhormonal antiepileptic drugs). The RR risk ratio was calculated using Review Manager 5.2 
(http://community.cochrane.org). A complete absence of seizures was considered as a favorable outcome. 150 children 
with confirmed West syndrome who received treatment at A.Yu.Ratner Pediatic Clinical Hospital №8 (Kazan, Russian 
Federation) were included into a retrospective observational study. 90 children treated with Tetracosactide in 
combination with AEDs were included into Group I. Group II consisted of 60 children who received any AEDs except 
Tetracosactide. The results showed that the effectiveness of Tetracosactide with complete absence of seizures as 
favorable outcome with short-term observation (at least 6 months) is higher than after treatment with other antiepileptic 
drugs in the absence of difference in safety. Long-term results of treatment (complete clinical remission during three 
years or more) did not have a significant difference. 
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Introduction. In 2015 the International League Against Epilepsy stated that there are currently no 
recommendations for prescribing antiepileptic drugs for children in the first 3 years of life with epilepsy proved by 
evidence-based medicine on the level A. The incidence of epilepsy in early childhood is the highest of all age groups. 
The most common seizures in children during the first three years of life are epileptic spasms and febrile seizures [1]. 
The authors of the Cochrane review on the treatment of infantile spasms (2013) concluded that most of the available 
research on the therapy of infantile spasms was methodologically weak and had a high risk of biased results [2]. Based 
on their findings, the ILAE Commission of Pediatrics recommends the use of Adrenocorticotropic hormone (ACTH) for 
short-term control of epileptic spasms (level B recommendation), and oral steroids are probably effective in short-term 
control of spasms (level C recommendation) [1, 2]. 
Since 1958, adrenocorticotropic hormone therapy (ACTH) has been the preferred method for treating West 
syndrome [3]. At the same time, researchers refer to the presence of serious side effects in treatment with ACTH. In 
recent decades, a number of new antiepileptic drugs have been used in clinical practice for the treatment of West 
syndrome. Preliminary positive results of monotherapy or combined treatment of West syndrome with Lamotrigine, 
Felbamate, Levetiracetam, Zonisamide, and Topiramate were reported in non-randomized trials conducted primarily by 
the manufacturers themselves [4–6]. However, subsequent studies did not universally confirm the first positive reports 
on the high effectiveness of these drugs [7, 8]. 
Since 2009, the FDA has approved Vigabatrin as a drug for the treatment of infantile spasms in the United 
States. Outside the USA, a number of prospective studies have compared Vigabatrin with placebo or other methods of 
treatment [9] and demonstrated that Vigabatrin is effective in the treatment of infantile spasms in most cases regardless 
of etiology, but it is the most effective in patients with tuberous sclerosis. Vigabatrin, as a rule, was well tolerated. 
Nevertheless, its use is associated with loss of peripheral vision in some patients [10]. American researchers believe that 
in children with tuberous sclerosis, Vigabatrin should be considered as an initial therapy for infantile spasms [11]. This 
drug is a good alternative for patients with an inadequate response to ACTH, or in the presence of contraindications or 
intolerance to ACTH [12]. 
Since the first description of infantile spasms, at least 30 drugs for their treatment have been tried and 
described, but the issue of optimal treatment remains problematic due to the large variability of therapy, uncertain 
dosing regimens, adverse reactions, incomplete therapeutic response, and, consequently, poor long-term prognosis for 
psychomotor development and the subsequent development of other types of seizures [2]. 
West syndrome, especially its symptomatic variant, is the result of polyethiologic, severely affected brain 
lesions that occurred in the early stages of development. One of the main tasks in its therapy is to relieve the seizures as 
urgently and fully as possible, since it is the presence of seizures and hypsarrhythmia that adversely affects the 
development of cognitive and motor functions of a child [13]. Therefore, effective treatment of West syndrome would  
be considered a therapy that provides complete control of infantile spasms [14]. Currently, there is a large number of 
antiepileptic drugs and schemes of combination therapy recommended for the treatment of West syndrome. At the same 
time, none of existing antiepileptic drugs guarantees the onset of rapid and prolonged clinical remission. In addition, 
many antiepileptic drugs only reduce the number of seizures, without ensuring their complete suppression [15]. The 
choice of optimal treatment tactics still remains debatable. The effectiveness of various drugs used in the treatment of 
infantile spasms is also difficult to assess due to the short period of patient observation and the lack of information on 
long-term results [2]. In 2017, O'Callaghan et al. published a randomized multicenter open-label trial on the study of 
safety and efficacy of hormonal treatment versus hormonal treatment with Vigabatrin for infantile spasms, which 
demonstrated the benefit of combined hormone and Vigabatrine treatment compared to monotherapy with hormones. 
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However, the authors again evaluated the effectiveness of therapy only in the case of short-term follow-up: the 
maximum follow-up was 18 months [16]. 
The purpose of this study was to provide a comparative retrospective assessment of short-term and long-term 
outcomes of combined therapy with the inclusion of Tetracosactide in comparison with other antiepileptic  drugs 
(AEDs) in West syndrome. 
Materials and methods. We conducted a retrospective analysis of the pharmacotherapy in 150 children who 
received inpatient West syndrome treatment in 2000–2015 at A.Yu.Ratner Pediatric Clinical Hospital No. 8 (Kazan, 
Russia). The inclusion criteria: a) proved diagnosis of West syndrome, b) the presence of antiepileptic treatment (mono- 
or poly-therapy). The outpatient phase of the study was conducted at the Cabinet for the Diagnosis and Treatment of 
Epilepsy and Paroxysmal Conditions where the additional information was obtained on the catamnesis of children who 
were first diagnosed with West syndrome while at the hospital. Duration of observation: not less than 3.5 years.  
Average age of children: 4 – 14.5 years old. The onset of the disease: 60 children – at 6 months; 82 children – prior to 1 
year; 8 children – after they turned 1 year old. 
The work was performed within the frames of research on clinical neurology and epilepsy conducted at 
Kazan Federal University [17–20]. 
The research involved pharmacoepidemiological, analytical, and statistical methods. The results were 
processed using the Microsoft Excel program package. The risk ratios (RR) and their confidence intervals (CIs) were 
calculated using the Revman 5.0 Software program. A favorable outcome of the treatment was clinical remission 
(complete absence of seizures of any type). In the statistical processing of the results, differences at p<0.05 were 
considered reliable. 
Results. In patients included into the study, 141 of 150 (94%) were diagnosed with a symptomatic West 
syndrome; 6% (9/150) had a cryptogenic variant of the West syndrome. The gender distribution of patients with West 
syndrome was somewhat dominated by boys: 93 (62%) male and 57 (38%) female children. 
All children with West syndrome were divided into 2 groups. Group I (study group) included 90 children 
with West syndrome (60% of the total number of patients) who received Tetracosactide (a synthetic analog of ACTH; 
international non-proprietary name Synacthen Depot) for the reduction of infantile spasms in combination with other 
AEDs. Tetracosactide (Synacthen Depot) was administered intramuscularly in doses according to the manufacturer’s 
instructions (https://www.rlsnet.ru/mnn_index_id_1193.htm). 
The course of Tetracosactide injections was performed in patients either simultaneously with the onset of 
AED therapy (for example, with valproic acid preparations) or after inefficient use of various AEDs. In this case, 
therapy with valproate or other AEDs remained as supporting. 
Group II (comparison group) included 60 children with West syndrome (40% of the total number of patients) 
who took AEDs, except Tetracosactide, as mono- or poly-therapy to relieve infantile spasms. The mono- and poly- 
therapy variants used in the treatment of West syndrome in children in groups I and II are presented in Table 1 and 
Table 2. 
Table 1. Treatment options in Group I 
Type of mono- and poly-therapy in group I (studies) Number of patients, abs/n 
(%) 
VA*, Tetracosactide 76 (85%) 
VA, Topiramate, Tetracosactide 7 (8%) 
VA, Carbamazepine, Tetracosactide 3 (3%) 
VA, Levetiracetam, Tetracosactide 1 (1%) 
VA, Levetiracetam, Topiramate, Tetracosactide 1 (1%) 
VA, Ethosuximide, Tetracosactide 1 (1%) 
VA, Carbamazepine, Levetiracetam, Vigabatrin, Tetracosactide 1 (1%) 
* VA – Valproic acid 
Table 2. Treatment options in Group II 
Type of mono- and poly-therapy in Group II Number of patients, abs/n=60 (%) 
Valproic acid 24 (40%) 
Topiramate 1 (2%) 
VA*, Succinamide 2 (3%) 
VA, Carbamazepine 1 (2%) 
VA, Topiramate 9 (15%) 
VA, Benzodiazepine 2 (3%) 
VA, Levetiracetam 2 (3%) 
VA, barbiturates 3 (5%) 
VA, 2 or more antiepileptic drugs 16 (27%) 
* VA – Valproic acid 
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All patients in both groups were comparable in age, sex, neurological status, gestational age at birth, and 
severity of the disease. 
A comparative analysis of the remission onset from the start of treatment in the two study groups showed that 
significantly faster complete remission was achieved when introducing Tetracosactide in patients with West syndrome. 
After 2 weeks of Tetracosactide treatment, seizures in 68 patients (76% of the total number of patients) 
stopped. In Group II, only 1 patient (4% of the total number of patients) had a favorable outcome. When comparing risk 
ratio parameters, the effectiveness of Tetracosactide 2 weeks from the start of treatment in Group I is significantly 
higher than in Group II, RR=45.33; 95% CI [6.47–317.71], p=0.0001. 
Further, response to therapy (2 months from the start of treatment) was also better in children receiving 
Tetracosactide: 69 of 90 patients (77%) achieved clinical remission in Group I and only 13 of 60 patients (22%) had a 
favorable outcome (absence of epileptic seizures) in Group II, RR=3.54; 95% CI [2.16–5.8], p<0.00001. Similarly, we 
calculated the risk ratio (the number of patients with full remission) 6 months later: 69 of 90 (77%) in Group I, 36 of 60 
(60%) in Group II, RR=1.28 95% CI [1.01–1.62]; p=0.04. 
In children with West syndrome in Group II (comparison group), the time to remission was more uncertain 
and the number of patients in remission reached the same level as in Group I only 1 year after treatment: 71 of 90 (79%) 
in Group I, 43 of 60 patients (72%) in Group II, RR=1.10 95% CI [0.91–1.33]; p=0.33. In the analysis of long-term 
outcomes (with complete clinical remission after 3 years considered the favorable outcome), the number of patients 
without seizures also did not differ statistically in the two groups: 62 of 90 patients (69%) in Group I and 37 of 60 
patients (62%) in Group II, RR=1.12; 95% CI [0.88–1.42], p=0.75. 
Analysis of undesirable drug reactions in the treatment with antiepileptic drugs in both groups showed the 
following: in Group I, 26 of 90 children (29%) had various side effects during the period of the treatment with 
Tetracosactide. The most common complaints were anxiety, crying (19 out of 90, 21%), Cushing's syndrome (6 out of 
90, 7%), and weakness and drowsiness (5 out of 90, 6%). 
A single child (1/90; 1%) manifested meningoencephalitis during the treatment with Tetracosactide. 
However, in the catamnesis, we did not observe any residual phenomena. In Group II, adverse events were reported in 
11 of 60 patients (18%). The spectrum of side effects in the treatment of certain AEDs recorded in the treatment of 
children in the second group is presented in Table 3. 
 
Table 3. Side effects of AEDs in Group II (comparison group) 
AED Side effects Number of patients who had side 
effects/number of patients taking 
this AED (%) 
Valproic acid Abdominal pain, nausea, vomiting, drowsiness, 
allergic reactions 
10/59 (17%) 
Levetiracetam Expressed anxiety, crying 2/3 (33%) 
Topiramate Refusal to eat, weight loss, inhibition, 
drowsiness, severe anxiety, sleep disturbance, 
increased salivation 
6/11 (55%) 
Clonazepam Lethargy, drowsiness, excessive drooling 4/5 (80%) 
Carbamazepine Allergic reaction, drowsiness, vomiting, 




Discussion. We calculated the risk ratios in Group I and Group II where the indicator was an unfavorable 
outcome: the number of patients with side effects. Risk Ratio RR=1.58; 95% CI [0.84–1.58], (p=0.15) indicates that 
there is no reliable difference between these groups with respect to AED safety. 
The literature mentions the marked adverse reactions observed in the treatment of ACTH, such as fulminant 
infection, immunosuppression, arterial hypertension [21]. However, in this group of children, such  severe reactions 
were not observed when introducing Tetracosactide into the regimen. This can be explained by the fact that the 
minimum doses of Tetracosactide recommended in the instructions for the drug were used for treatment. 
Despite the fact that the long-term results of therapy of children with West syndrome with inclusion of 
Tetracosactide in the regimen of therapy do not differ from the results of the use of antiepileptic drugs without the use  
of Tetracosactide, rapid cessation of seizures (within the first two weeks after the start of treatment) and their complete 
absence during 1 year from the start of treatment in most patients with Tetracosactide treatment has a great importance 
for the psychomotor development of the patients. 
The results obtained make it possible to determine the tactics for treating patients with West syndrome. The 
principal property of the therapeutic agent that determines the long-term prognosis for the development of cognitive and 
motor functions in children with West syndrome is a rapid and complete control of seizures and inhibition of 
hypsarrhythmia on the EEG, which provides the introduction of adrenocorticotropic hormone into the  treatment 
regimen of these patients. The cessation of infantile spasms almost immediately after the introduction of Tetracosactide 
into the treatment regimen allows early rehabilitation of these children, reduces the severity of cognitive and motor 
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disorders, reduces the need for antiepileptic drugs in poly-therapy, and, as a result, the risk of a large number of 
unwanted drug reactions. 
Conclusion. A comparative analysis of the treatment effectiveness in two groups (Group I with the use of 
Tetracosactide and Group II without the use of Tetracosactide) showed that the effectiveness of Tetracosactide (with 
complete absence of seizures as favorable outcome) with short-term observation (at least 6 months) is higher than when 
treated with other antiepileptic drugs in the absence of difference in safety; and with long-term follow-up (three years or 
more), the effectiveness of Tetracosactide is comparable to that of other antiepileptic drugs. 
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